Compare MSN & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSN | IMNN |
|---|---|---|
| Founded | 1948 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 10.8M |
| IPO Year | 1995 | 2000 |
| Metric | MSN | IMNN |
|---|---|---|
| Price | $0.45 | $2.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 23.1K | ★ 28.9K |
| Earning Date | 02-17-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $77,829,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $0.37 |
| 52 Week High | $0.85 | $9.32 |
| Indicator | MSN | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 39.24 |
| Support Level | $0.39 | $2.59 |
| Resistance Level | $0.46 | $3.24 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 64.93 | 19.49 |
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.